Biotech

All Articles

iTeos- GSK's TIGIT celebrity shows purposeful enhancement

.After revealing a phase 3 launch based upon positive midstage end results, iTeos as well as GSK are...

More collaborative FDA can accelerate uncommon condition R&ampD: record

.The FDA should be actually more available and collective to unleash a rise in commendations of unco...

Zenas, MBX, Bicara scalp to Nasdaq in warm time for biotech IPOs

.It's an abnormally occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicar...

Atea's COVID antiviral neglects to stop hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has actually neglected an additional COVID-19 trial, but the biotec...

Neurocrine's offer to spare schizophrenia prospect falls short

.Neurocrine Biosciences' mental illness plan pivot has stopped working. The biotech was not able to ...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has created a late entry to the radioligand event, paying 100 million euros ($ 110 thousand)...

F 2G increases $100M for 2nd effort to obtain brand-new antifungal to market

.After F2G's very first attempt to get a brand-new class of antifungal to market was actually derail...

Moderna targets $1.1 B in R&ampD spending slices, drops 5 programs surrounded by profits pressures

.Moderna has promised to reduce R&ampD investing through $1.1 billion by 2027. The selection to retr...

Sanofi's $80M bet on Pivot dystrophy medicine ends in phase 3 fail

.Just 4 months after Sanofi bet $80 thousand in upfront money on Fulcrum Therapeutics' losmapimod, t...

Oncternal assets sinks 60% amid discharges, trial terminations

.Cancer company Oncternal Therapies is folding all its scientific tests and also giving up team, tra...